2025-12-04

2025

Crowned with Five Certifications Pioneering New Breakthroughs in the Industry

Learn more  

2025-11-10

“China’s Strength” Emerges in the Pet Biopharmaceutical Sector — Insights into the Breakthroughs of Chinese Pet Pharmaceutical Companies from the Approval of Two Class II New Veterinary Drugs

Recently, in a laboratory at China Pharmaceutical City in Taizhou, Jiangsu Province, recombinant feline omega-interferon is undergoing pre-market stability studies, with the compilation and analysis of key data now in the final stages. Researchers are holding their breath, as this small pharmaceutical product—alongside the “Miaobeihu” feline trivalent inactivated vaccine, which was just approved here two months ago—represents not only a breakthrough from zero to one in China’s pet biopharmaceutical sector, but also signals the emergence of a formidable “Chinese force” in an industry long dominated by international giants.

Learn more  

2025-10-15

Another Breakthrough! BioAlly’s Recombinant Feline Omega-Interferon Has Been Approved as a National Class II New Veterinary Drug!

On September 16, 2025, the Ministry of Agriculture and Rural Affairs issued Announcement No. 949: Recombinant feline interferon-α, independently developed by Taizhou BioAlly Biotechnology Co., Ltd., has been successfully approved for registration as a Class II new veterinary drug at the national level. This marks China’s first—and the world’s second—approved recombinant feline interferon, as well as the world’s first interferon product with dual applications: both injectable and ophthalmic. This milestone breakthrough not only signifies that China’s research and development in pet genetic engineering pharmaceuticals has entered the ranks of international leaders, but also fully demonstrates BioAlly’s outstanding capacity for technological innovation. Committed to independent R&D.

Learn more  

2025-10-13

MeowCare Standard Immunization Protocol

Throughout a cat’s life, vaccination serves as a robust line of defense, effectively warding off disease and safeguarding their health. Now, let’s explore the standardized procedures for Miao Beihu’s immunization program, ensuring that every feline companion thrives and grows strong.

Learn more  

2024-03-30

Donation Ceremony Held for the Zhejiang University Education Foundation by Taizhou Bolaideli Biotechnology Co., Ltd.

On the morning of March 27, a donation ceremony was held at the Center for Veterinary Medicine of Zhejiang University to mark the contribution made by Taizhou Bolaideli Biotechnology Co., Ltd. to the Zhejiang University Education Foundation. The ceremony was attended by Wang Hongwei, Chairman of Taizhou Bolaideli Biotechnology Co., Ltd.; Gao Peiye, New Media Marketing Manager; Zhou Jiyong, Director of the Center for Veterinary Medicine at Zhejiang University; and Man Feng, Deputy Director of the Office for Development and External Relations and Deputy Secretary-General of the Education Foundation, among others. The event was chaired by Wang Huanan, Secretary of the Party Branch of the Center for Veterinary Medicine at Zhejiang University.

Learn more  

2024-03-07

Exciting news: the nomination process is now officially underway for the “Bolaideli” 16th East–West Small Animal Clinical Veterinarians Conference Outstanding Young Veterinarian Award!

The 16th East–West Small Animal Clinical Veterinarians Conference is scheduled to be held from May 29 to 31, 2024, at the picturesque Hangzhou International Expo Center. As in previous years, the highly anticipated “Outstanding Young Veterinarian Award” ceremony will be solemnly presented during the conference’s opening ceremony. Over the past 15 years, Bolaideli, in collaboration with the East–West Conference, has consistently identified and recognized outstanding young veterinarians, injecting fresh talent and vitality into the companion animal healthcare industry, strengthening its collective momentum, and driving its continued development.

Learn more